DNAJC5 Antibody

What is DNAJC5 and why is it important in neurodegenerative disease research?

DNAJC5, also known as Cysteine String Protein α (CSPα), is a member of the HSP40 (DNAJ) family of proteins that functions as a co-chaperone of HSC70. It contains three structural domains: an N-terminal J domain, a cysteine string (CS) central domain that is highly palmitoylated and anchors the protein to late endosomes, and a disordered C-terminal domain .

DNAJC5 has gained significant research interest because it plays a crucial role in controlling the extracellular release of several neurodegenerative disease-associated proteins, including α-synuclein, tau, and TDP-43 . Mutations in DNAJC5, particularly L115R and L116Δ in the CS domain, cause adult-onset neuronal ceroid lipofuscinosis (ANCL), a neurodegenerative disorder characterized by accumulation of lipofuscin in neurons .

Research methodologies involving DNAJC5 typically include:

• Protein trafficking and secretion assays

• Subcellular localization using fluorescence microscopy

• Palmitoylation and post-translational modification studies

• Protein-protein interaction studies with HSC70 and client proteins

What applications are DNAJC5 antibodies validated for in neuroscience research?

DNAJC5 antibodies have been validated for multiple applications in neuroscience research:

When selecting a DNAJC5 antibody for neuroscience research, consider:

• Species reactivity (human, mouse, rat, etc.)

• The specific epitope recognized (different domains may yield different results)

• Clonality (polyclonal vs. monoclonal)

• Validation in your specific experimental system

How do I select the optimal DNAJC5 antibody for my specific experimental design?

Selection of the optimal DNAJC5 antibody should follow these methodological considerations:

• Target epitope analysis: Different DNAJC5 antibodies recognize different regions of the protein. For studying full-length DNAJC5, antibodies targeting the N-terminal J domain or C-terminal regions work well. For investigating mutations in the CS domain (e.g., L115R, L116Δ), choose antibodies that recognize epitopes distant from these regions .

• Post-translational modification sensitivity: If studying palmitoylated vs. non-palmitoylated forms of DNAJC5, select antibodies that aren't affected by this modification. The search results show that DNAJC5 appears as two distinct bands on SDS-PAGE corresponding to palmitoylated (P-DNAJC5) and non-palmitoylated (NP-DNAJC5) forms .

• Experimental application matching:

  • For subcellular fractionation studies: antibodies validated for distinguishing membrane-bound vs. cytosolic DNAJC5

  • For oligomerization studies: antibodies that can detect SDS-resistant oligomers (HMW-DNAJC5)

  • For co-localization studies: antibodies compatible with dual-labeling strategies

• Host species compatibility: Consider the host species when designing multi-labeling experiments to avoid cross-reactivity .

How can I effectively use DNAJC5 antibodies to investigate the MAPS (Misfolding-Associated Protein Secretion) pathway?

The MAPS pathway represents an unconventional secretion mechanism for misfolded proteins that is regulated by DNAJC5. To effectively investigate this pathway using DNAJC5 antibodies:

• Co-immunoprecipitation studies: Use DNAJC5 antibodies to pull down DNAJC5 and its interacting partners:

  • HSC70: A direct interaction partner in the MAPS pathway

  • USP19: Acts upstream of HSC70 and DNAJC5 in the pathway

  • SLC3A2/CD98hc: Critical for MAPS but dispensable for microautophagy

  • Client proteins: α-synuclein, tau, and TDP-43

• Secretion assay design: Design experiments that differentiate between conventional and unconventional secretion:

  • Cell culture: Wash cells to remove serum proteins, then incubate in serum-free media for 6 hours

  • Media fractionation: Use differential centrifugation to separate vesicular and non-vesicular secreted proteins

  • Detection: Use sensitive methods like nanoluciferase-tagged client proteins for quantitative detection

• Pathway inhibition/stimulation studies:

  • Quercetin (DNAJC5 inhibitor): Dose-dependent inhibition of α-syn secretion

  • Bafilomycin A1 (lysosomal ATPase inhibitor): Stimulates α-syn secretion in a DNAJC5-dependent manner

  • 2-bromopalmitic acid (2-BA): Inhibits DNAJC5 palmitoylation

• CRISPR knockout validation: Compare phenotypes between wild-type and DNAJC5 KO cells to confirm pathway specificity .

What are the critical considerations when using DNAJC5 antibodies to study neurodegenerative disease mechanisms?

When using DNAJC5 antibodies to study neurodegenerative diseases, consider these critical methodological aspects:

• Domain-specific detection: DNAJC5 mutations associated with ANCL (L115R and L116Δ) affect palmitoylation and promote protein aggregation. Use antibodies that can differentiate between:

  • Wild-type vs. mutant DNAJC5

  • Palmitoylated vs. non-palmitoylated forms

  • Monomeric vs. oligomeric states

• Model system selection: Different cell types show varying DNAJC5 palmitoylation profiles:

  • HEK293T cells: Both P-DNAJC5 and NP-DNAJC5 forms present

  • MDA-MB-231 and HeLa cells: Predominantly P-DNAJC5 form

  • Neuronal models: Differentiated SH-SY5Y cells and mouse/human dopaminergic neurons show distinct expression patterns

• Secretion vs. degradation differentiation:

  • Verify intracellular protein reduction is due to secretion rather than degradation

  • Control experiments: proteasome inhibition (epoxomicin), mRNA quantification (qRT-PCR)

  • Toxicity assessment: Ensure cell viability during DNAJC5 overexpression

• Client protein selectivity:

  • Validated DNAJC5 clients: tau, α-synuclein, TDP-43

  • Non-clients: polyQ-25 fragments

  • Confirmation methodology: combined overexpression and secretion assays

How can I distinguish between different oligomeric states of DNAJC5 using specific antibodies?

DNAJC5 forms SDS-resistant oligomers that can be detected using specific antibody-based techniques. To differentiate between monomeric and oligomeric states:

• SDS-PAGE and immunoblotting optimization:

  • Use whole-gel immunoblotting to detect high-molecular-weight (HMW) oligomers

  • Look for ladder-like bands with higher apparent molecular weight than P-DNAJC5 and NP-DNAJC5

  • J domain deletion enhances visible oligomerization

• Sample preparation considerations:

  • Reducing conditions: HMW-DNAJC5 migration is not altered by reducing agents, indicating non-disulfide bonding

  • Heat treatment: Avoid excessive heating which may disrupt oligomers

  • Detergent selection: Use mild detergents for initial lysis

• Size fractionation techniques:

  • Gel filtration chromatography: Separates HMW-DNAJC5 according to apparent size

  • Analysis reveals discrete protein species rather than insoluble aggregates

• Enhanced oligomerization detection:

  • Bafilomycin A1 treatment induces more DNAJC5 oligomer formation

  • C-terminal truncation constructs (ΔC10, ΔC20, ΔC30, ΔC40) form detectable oligomers

What protocol modifications are needed to detect palmitoylated versus non-palmitoylated forms of DNAJC5?

Detection of palmitoylated versus non-palmitoylated DNAJC5 requires specific methodological considerations:

• SDS-PAGE optimization:

  • Palmitoylated DNAJC5 (P-DNAJC5) shows lower mobility compared to non-palmitoylated DNAJC5 (NP-DNAJC5)

  • Use appropriate percentage gels (10-12%) for optimal separation

  • Extended running times may improve separation of these forms

• Subcellular fractionation protocol:

  • P-DNAJC5 associates predominantly with membrane fractions

  • NP-DNAJC5 is primarily found in cytosolic fractions

  • Use differential centrifugation to separate these pools

• Depalmitoylation assay:

  • Treat samples with hydroxylamine (HA) overnight to remove palmitate groups

  • This shifts P-DNAJC5 mobility to match NP-DNAJC5 on gels

  • Include untreated controls for comparison

• Palmitoylation inhibition:

  • 2-bromopalmitic acid (2-BA) treatment inhibits palmitoyl transferases

  • Analyze redistribution from membrane to cytosol

  • Compare with DNAJC5 L115R mutant (palmitoylation-deficient) as a control

• Blotting membrane selection and antibody incubation:

  • PVDF membranes may retain palmitoylated proteins better than nitrocellulose

  • Optimize blocking conditions to prevent non-specific binding

  • Use antibodies that recognize epitopes unaffected by palmitoylation state

What controls should be included when studying DNAJC5-mediated protein secretion using antibody-based techniques?

Rigorous controls are essential when studying DNAJC5-mediated protein secretion:

• Intracellular contamination controls:

  • Include markers for cell lysis/damage (LDH, GAPDH, tubulin)

  • Verify absence of intracellular markers in conditioned media

  • Exclude apoptotic cells using flow cytometry or viability assays

• Secretion pathway verification:

  • Conventional vs. unconventional secretion: Test Brefeldin A sensitivity

  • Exosome markers: Alix, CD9, CD63, Flot-2

  • Vesicle-free secretion markers: PDI (negative control for exosomes)

• Genetic manipulation controls:

  • DNAJC5 knockout cell lines as negative controls

  • DNAJC5 mutants: L115R (palmitoylation-deficient), ΔJ (J-domain deletion)

  • shRNA knockdown with non-targeting shRNA controls

• Quantification standards:

  • For mass spectrometry: 15N-labeled internal standards

  • For luminescence assays: Standard curves with purified proteins

  • For ELISAs: Appropriate calibration standards

• Fractionation quality controls:

  • Differential centrifugation: 2k, 10k, 25k, and 100k ×g fractions

  • Sucrose gradient flotation: 10%/40%/60% interfaces

  • Gel filtration: Calibration with known molecular weight standards

How do I troubleshoot inconsistent DNAJC5 antibody performance across different experimental systems?

Troubleshooting inconsistent DNAJC5 antibody performance requires systematic analysis:

• Cell/tissue-specific expression variations:

  • DNAJC5 expression levels differ between cell types

  • Palmitoylation states vary (HEK293T vs. MDA-MB-231 and HeLa cells)

  • Neuronal cells (SH-SY5Y, primary neurons) have distinct expression patterns

• Antibody epitope accessibility issues:

  • Post-translational modifications may mask epitopes

  • Protein-protein interactions can block antibody binding

  • Fixation methods affect epitope recognition (for IHC/ICC)

• Protocol optimization strategy:

  • Titrate antibody concentrations (1:200-1:50000 depending on application)

  • Test multiple blocking agents (BSA, milk, serum)

  • Adjust incubation times and temperatures

  • Try different antigen retrieval methods for fixed samples

• Cross-reactivity assessment:

  • DNAJC5 has homologs (DNAJC5β, DNAJC5γ)

  • Verify antibody specificity using knockout controls

  • Pre-adsorption tests with immunizing peptides

• Sample preparation considerations:

  • Different lysis buffers affect protein solubility

  • SDS-resistant oligomers require specialized extraction

  • Membrane-associated forms need detergent solubilization

How should I interpret DNAJC5 antibody staining patterns in relation to protein secretion pathways?

Interpreting DNAJC5 antibody staining patterns requires understanding its subcellular distribution in relation to secretory pathways:

• Normal subcellular localization patterns:

  • Diffuse cytoplasmic: Non-palmitoylated DNAJC5

  • Punctate vesicular: Palmitoylated DNAJC5 associated with late endosomes/lysosomes

  • Co-localization with RAB9 and LAMP1: Indicates endolysosomal localization

• Secretion pathway intermediate identification:

  • DNAJC5 in enlarged endosomes (using Rab5 Q79L): Indicates a secretory intermediate

  • Luminal vs. peripheral endosomal localization: Distinguishes membrane translocation events

  • Co-localization with client proteins (α-synuclein): Suggests active secretion processes

• Mutant vs. wild-type comparison:

  • L115R mutant: Dispersed cytosolic pattern, not internalized into enlarged endosomes

  • L115R prevents client protein entry into endosomes

  • J-domain deletion (ΔJ): Enhanced endolysosomal translocation

• Protease protection assay interpretation:

  • Partial resistance to proteinase K digestion indicates membrane sequestration

  • Complete digestion in the presence of detergents confirms membrane protection

  • Quantify the protected fraction to estimate secretion efficiency

How do I analyze complex data from DNAJC5 knockout/knockdown experiments in neurodegenerative disease models?

Analysis of complex DNAJC5 knockout/knockdown data requires careful consideration of multiple factors:

• Baseline secretion vs. stimulated secretion:

  • Basal secretion: Accumulation of secreted proteins over time without DNAJC5 overexpression

  • Stimulated secretion: Enhanced by DNAJC5 overexpression or BaFA1 treatment

  • Differential effects across cell types (HEK293T vs. differentiated neurons)

• Client protein-specific effects:

  • Compare multiple client proteins (α-synuclein, tau, TDP-43) within the same experiment

  • Normalize to intracellular protein levels to account for expression differences

  • Assess selective effects on disease-associated vs. non-disease proteins

• Statistical analysis approach:

  • Use appropriate statistical tests for secretion assays (typically ANOVA with post-hoc tests)

  • Account for biological replicates (n≥3) and technical variability

  • Present data as fold-change relative to control conditions

• Compensatory mechanisms assessment:

  • Check for upregulation of alternative secretion pathways

  • Monitor autophagy markers (LC3-I/II conversion)

  • Evaluate other DNAJ family members' expression

• Correlation with disease phenotypes:

  • Lipofuscinosis development in ANCL models

  • Neurodegeneration markers in relevant models

  • Protein aggregation patterns in secretion-deficient conditions

How can I differentiate between DNAJC5-mediated unconventional secretion and exosome-mediated release using antibody-based techniques?

Differentiating between DNAJC5-mediated unconventional secretion and exosome-mediated release requires strategic experimental design:

• Medium fractionation protocol:

  • Differential centrifugation: 2k (cell debris), 10k (large vesicles), 100k ×g (exosomes)

  • Analysis of supernatant (soluble proteins) vs. pellet (vesicular proteins)

  • Immunoblot for exosome markers (Alix, CD9) and soluble protein markers

• Sucrose gradient flotation analysis:

  • Layer media concentrate in 60% sucrose and overlay with 40% and 10% sucrose

  • Centrifuge overnight at 150,000 ×g

  • Collect fractions and analyze by immunoblot

  • Exosomal proteins float at 10%/40% interface, while soluble proteins remain at bottom

• Size characterization techniques:

  • Gel filtration chromatography: Separates by hydrodynamic radius

  • Compare elution profiles with standards (monomers, dimers, tetramers)

  • Quantify relative distribution across fractions

• Membrane protection assays:

  • Protease protection: Resistance to proteases indicates membrane enclosure

  • Detergent sensitivity: Addition of Triton X-100 disrupts membrane protection

  • Quantify protected vs. unprotected fractions

• Client protein state analysis:

  • DNAJC5-mediated secretion produces primarily soluble monomers

  • Exosomal release may include various oligomeric states

  • Combined immunoblot and native gel analysis to characterize secreted forms

How are cutting-edge DNAJC5 antibody techniques advancing our understanding of protein quality control in neurodegeneration?

Recent advances in DNAJC5 antibody applications are revolutionizing our understanding of protein quality control:

• Super-resolution microscopy applications:

  • Visualizing DNAJC5-mediated protein translocation into endolysosomes

  • Tracking the fate of client proteins along the secretory pathway

  • Resolving nanoscale organization of DNAJC5 oligomers at membrane interfaces

• Live-cell imaging innovations:

  • Self-labeling tag approaches (HaloTag-DNAJC5) enabling multicolor live imaging

  • Enlarged endosome models (Rab5 Q79L) to visualize secretory intermediates

  • Real-time monitoring of client protein translocation events

• Proximity labeling techniques:

  • BioID or APEX2 fusions to map the DNAJC5 interactome

  • Identification of transient interaction partners during secretion

  • Spatial mapping of DNAJC5 associations in different subcellular compartments

• Advanced cell models:

  • hiPSC-derived midbrain dopaminergic neurons for Parkinson's disease modeling

  • CRISPR-engineered DNAJC5 mutant cell lines mimicking ANCL mutations

  • Lentiviral transduction of mESCs for stable expression in differentiated neurons

What are the methodological challenges in studying DNAJC5 interactions with other chaperone systems using antibody-based approaches?

Studying DNAJC5 interactions with other chaperone systems presents several methodological challenges:

• Co-immunoprecipitation optimization:

  • Chaperone interactions are often transient and ATP-dependent

  • Use crosslinking approaches to stabilize transient complexes

  • Include ATP/ADP in buffers to modulate interaction states

  • Antibody selection to avoid epitopes in interaction interfaces

• Client specificity determination:

  • DNAJC5 shows selectivity for certain misfolded proteins (α-synuclein, tau, TDP-43)

  • Map binding domains using domain deletion/mutation approaches

  • Competition assays between different client proteins

  • Correlation between binding affinity and secretion efficiency

• Functional relationship with HSC70:

  • J-domain independent activities in protein secretion

  • Hierarchical relationship with USP19 (acts upstream of HSC70 and DNAJC5)

  • Distinguish between canonical chaperone function and secretion function

• Integration with other quality control systems:

  • ESCRT-dependent endosomal microautophagy (eMI)

  • Misfolding-associated protein secretion (MAPS)

  • Uncoupling between these processes in disease states

How should researchers integrate antibody-based findings with other methodologies to understand DNAJC5's role in disease pathogenesis?

Integrating antibody-based findings with complementary methodologies provides a comprehensive understanding of DNAJC5 in disease:

• Multi-omics integration strategy:

  • Proteomics: Identify secreted proteins in DNAJC5 WT vs. KO/mutant systems

  • Transcriptomics: Assess compensatory gene expression changes

  • Metabolomics: Evaluate metabolic consequences of dysregulated protein secretion

  • Lipidomics: Analyze lipid changes associated with lipofuscinosis

• In vivo validation approaches:

  • Animal models with DNAJC5 mutations or conditional knockouts

  • Behavioral testing correlated with biochemical changes

  • Tissue-specific expression/deletion to identify vulnerable cell populations

• Patient-derived samples analysis:

  • iPSC-derived neurons from ANCL patients

  • CSF/plasma biomarker studies of secreted proteins

  • Post-mortem tissue examination for DNAJC5 localization and client protein accumulation

• Therapeutic target validation:

  • Quercetin as a DNAJC5 inhibitor for modulating protein secretion

  • Palmitoylation modulators to rescue L115R mutant function

  • Screen for small molecules affecting DNAJC5 oligomerization

  • Evaluate consequences of manipulating the USP19-HSC70-DNAJC5 axis